Update of Potential Biomarkers in Risk Prediction and Monitoring of Atherosclerosis in Systemic Lupus Erythematosus to Prevent Cardiovascular Disease

被引:6
|
作者
Blachut, Dominika [1 ]
Przywara-Chowaniec, Brygida [1 ]
Tomasik, Andrzej [1 ]
Kukulski, Tomasz [1 ]
Morawiec, Beata [1 ]
机构
[1] Med Univ Silesia, Dept Cardiol 2, PL-41800 Zabrze, Poland
关键词
systemic lupus erythematosus; biomarkers; atherosclerosis; interferon signaling; cardiovascular risk; immune cells; REGULATORY T-CELLS; SUBCLINICAL ATHEROSCLEROSIS; ANTIPHOSPHATIDYLETHANOLAMINE ANTIBODIES; CLINICAL-MANIFESTATIONS; ENDOTHELIAL DYSFUNCTION; VASCULAR-DISEASE; HEART-DISEASE; RECEPTOR; INFLAMMATION; ADHESION;
D O I
10.3390/biomedicines11102814
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Systemic lupus erythematosus is a chronic connective tissue disease associated with an increased risk of premature atherosclerosis. It is estimated that approximately 10% of SLE patients develop significant atherosclerosis each year, which is responsible for premature cardiovascular disease that is largely asymptomatic. This review summarizes the most recent reports from the past few years on biomarkers of atherosclerosis in SLE, mainly focusing on immune markers. Persistent chronic inflammation of the vascular wall is an important cause of cardiovascular disease (CVD) events related to endothelial dysfunction, cell proliferation, impaired production and function of nitric oxide and microangiopathic changes. Studies on pathogenic immune mediators involved in atherosclerosis will be crucial research avenues for preventing CVD.
引用
收藏
页数:16
相关论文
共 50 条
  • [1] Cardiovascular disease in systemic lupus erythematosus: an update
    Liu, Yudong
    Kaplan, Mariana J.
    CURRENT OPINION IN RHEUMATOLOGY, 2018, 30 (05) : 441 - 448
  • [2] Lipids, cardiovascular disease and atherosclerosis in systemic lupus erythematosus
    Wierzbicki, AS
    LUPUS, 2000, 9 (03) : 194 - 201
  • [3] Systemic lupus erythematosus and cardiovascular disease: prediction and potential for therapeutic intervention
    McMahon, Maureen
    Hahn, Bevra H.
    Skaggs, Brian J.
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2011, 7 (02) : 227 - 241
  • [4] BIOMARKERS OF ATHEROSCLEROSIS IN SYSTEMIC LUPUS ERYTHEMATOSUS
    Ravenell, R. L.
    Shaftman, S.
    Cappuccio, M.
    Fleury, T.
    Dononhue, J.
    Zhu, H.
    Spence, D.
    Parker, T.
    Ueberroth, L.
    Oates, J.
    JOURNAL OF INVESTIGATIVE MEDICINE, 2009, 57 (01) : 370 - 370
  • [5] Cardiovascular disease in systemic lupus erythematosus: A comprehensive update
    Giannelou, Mayra
    Mavragani, Clio P.
    JOURNAL OF AUTOIMMUNITY, 2017, 82 : 1 - 12
  • [6] Markers of atherosclerosis and cardiovascular disease in patients with systemic lupus erythematosus
    Rednic, S
    Damian, LO
    Minodora, M
    Cristea, A
    Bolosiu, HD
    ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 : 436 - 436
  • [7] Cardiovascular Risk Measured by PREVENT Calculator and Disease Activity in Patients with Systemic Lupus Erythematosus
    Polina-Lugo, Rebeca L.
    Gonzalez Melendez, Aleydis
    Elizondo-Benitez, Maria F.
    Guajardo Aldaco, Andrea
    Dominguez-Guerra, Annette
    Limas-Martinez, Victoria P.
    Colunga Pedraza, Iris Jazmin
    Galarza-Delgado, Dionicio
    Azpiri-Lopez, Jose Ramon
    Arvizu-Rivera, Rosa Icela
    Cardenas-de la Garza, Jesus
    ARTHRITIS & RHEUMATOLOGY, 2024, 76 : 4113 - 4114
  • [8] Establishing a Risk Prediction Model for Atherosclerosis in Systemic Lupus Erythematosus
    Xing, Haiping
    Pang, Haiyu
    Du, Tian
    Yang, Xufei
    Zhang, Jing
    Li, Mengtao
    Zhang, Shuyang
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [9] Immune mechanisms associated with cardiovascular disease in systemic lupus erythematosus: A path to potential biomarkers
    Guzman-Martinez, Gabriela
    Maranon, Concepcion
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [10] Cardiovascular disease risk and pathogenesis in systemic lupus erythematosus
    Oliveira, Christopher B.
    Kaplan, Mariana J.
    SEMINARS IN IMMUNOPATHOLOGY, 2022, 44 (03) : 309 - 324